metastatic melanoma: the checkmate 067 and 069 trials
Published 6 years ago • 275 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:13
checkmate 067: nivolumab plus ipilimumab combination therapy in advanced melanoma
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
2:31
checkmate-069: spectacular results with combination therapy
-
3:45
update on checkmate 067, an advanced melanoma clinical trial
-
1:38
patients in checkmate 067 demonstrate durable complete responses
-
2:01
checkmate 172 trial of nivolumab for advanced melanoma: preliminary results
-
3:47
phase 3 checkmate 067 trial of nivolumab in untreated advanced melanoma
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma
-
0:59
checkmate 067: phase 3 trial of nivolumab in melanoma
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
2:31
dr. wolchok on updated checkmate-067 results for melanoma
-
1:33
dr. wolchok on the safety profile in checkmate-067 in melanoma
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
2:48
combining checkpoint blockade therapies in melanoma
-
0:58
combination nivolumab and ipilimumab shows efficacy in advanced melanoma
-
4:47
nivolumab chemotherapy combination treatment: checkmate649 and attraction-4
-
1:59
checkmate 238: nivolumab versus ipilimumab in stage iii melanoma
-
5:01
melanoma highlights from esmo 2021